Drug intelligence / Profile preview

DWC202407

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202407 is an investigational small molecule drug developed by Daewoong Pharmaceutical. As of June 2025, it is being studied in Phase 1 clinical trials to evaluate its pharmacokinetic and pharmacodynamic interactions with other investigational agents (DWP16001 and DWC202408) in healthy adult volunteers. The specific mechanism of action for DWC202407 has not been disclosed, and there are no approved indications or known adverse events reported at this stage. The drug is administered orally[3][1][2][4].

Other names: DWC-202407DWC202407DWC 202407

Beyond the preview

Go deeper on DWC202407.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202407.

Explore the full profile